

Technology Advisory Committee A Interests Register

Topic: Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]

Publication Date: 11/01/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Wasat Mansoor	Clinical expert	Financial	Professor Mansoor declared a financial Interest as he has previously received fees from BMS for attending an advisory board.	N/A	December 2020	N/A	It was agreed that his declarations would not prevent Professor Mansoor from providing expert advice to the committee.
Dr Elizabeth Smyth	Clinical expert	Financial	Dr Elizabeth Smyth as received honoraria, advisory board fees and travel support from Aptitude Health, Astra Zeneca, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Roche, Sai-Med, Servier, Zymeworks. She also declared an indirect interest for funding from BMS to the Southampton Clinical Trials Unit for the ELEVATE trial.	N/A	03.12.2020	N/A	It was agreed that her declarations would not prevent Dr Smyth from providing expert advice to the committee.